EUR/USD
1.16648
-0.013%
Gold
4594.68
-0.056%
Oil
60.004
0.600%
USD/JPY
159.009
0.539%
GBP/USD
1.34753
0.074%
GBP/JPY
214.274
0.620%
Real-time News
Google will develop and manufacture high-end mobile phones in Vietnam this year.On January 13th, Bio-Thera Solutions announced that its second board of directors held its 18th meeting on October 8th, 2024, and approved the "Proposal on Signing an Authorization License, Production, Supply and Commercialization Agreement for BAT2206". According to the agreement, Bio-Thera Solutions recently received a one-time milestone payment of US$2.5 million from Jireh Pharmaceuticals. This payment further replenishes the companys cash reserves and supports the companys subsequent pipeline development and internationalization strategy. As of the date of this announcement, BAT2206 injection has been approved for marketing by the U.S. Food and Drug Administration and the European Medicines Agency, with the registered brand name STARJEMZA® in the U.S. and Usymro® in Europe; a marketing application has been submitted to the National Medical Products Administration of China and is currently under review.On January 13, Henlius Biotech (02696.HK) announced that its Biologics License Application (BLA) for its self-developed Hanbetai® (bevacizumab injection) has been accepted by the U.S. Food and Drug Administration. The indications covered by this application include: (1) metastatic colorectal cancer; (2) first-line treatment of unresectable locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel; (3) recurrent adult glioblastoma; (4) treatment of metastatic renal cell carcinoma in combination with interferon-α; (5) epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer; and (6) treatment of persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.On January 13th, Sanwei Co., Ltd. announced that Ye Jiyue, one of the controlling shareholders and actual controllers, holds 375 million shares, accounting for 36.32% of the total share capital. He plans to transfer no more than 52.5893 million shares, representing 5.10% (inclusive) of the total share capital, through a negotiated transfer within three months after three trading days from the date of the announcement. This negotiated transfer will not result in a change of the companys controlling shareholder or actual controller, and does not involve a tender offer.Serbian President Aleksandar Vučić: The U.S. Treasury Department is expected to extend the operating license for the Russian-owned NIS oil company.
